Mark Penney

1.6k citations

18 papers · 1.1k indexed · h-index 15

Impact in

Internal Medicine top 10%
Neurology top 10%
- Neurological diseases and metabolism

Papers in ⓘ

Molecular Biology 7
Oncology 4
- Cancer-related Molecular Pathways 2

Co-authors: David A. Hilton (4 shared papers)Linda McCardle (2 shared papers)James W. Ironside (2 shared papers)Diane Ritchie (2 shared papers)P. G. Edwards (2 shared papers)Doha Hegazy (1 shared paper)Azra C. Ghani (1 shared paper)René van der Merwe (3 shared papers)
Journals: CPT Pharmacometrics & Systems Pharmacology (6 papers)Gastroenterology (2 papers)Journal of Clinical Pathology (1 paper)Journal of Orthopaedic Translation (1 paper)Blood (1 paper)
Partner nations: United Kingdom United States Sweden

In The Last Decade

Mark Penney

18 papers receiving 1.1k citations

Peers

Countries citing papers authored by Mark Penney

Since Specialization

Citations

This map shows the geographic impact of Mark Penney's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Penney with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Penney more than expected).

Fields of papers citing papers by Mark Penney

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Penney. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Penney. The network helps show where Mark Penney may publish in the future.

Co-authors

The 25 scholars most cited alongside Mark Penney, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Mark Penney Line = papers co-authored together Mark Penney links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

#	Work
1	Prevalence of lymphoreticular prion protein accumulation in UK tissue samples The Journal of Pathology ·David A. Hilton, Azra C. Ghani, Lisa Conyers, P. G. Edwards, Linda McCardle, Diane Ritchie, Mark Penney, Doha Hegazy, James W. Ironside	2004	293
2	Efficacy and Safety of MEDI2070, an Antibody Against Interleukin 23, in Patients With Moderate to Severe Crohn’s Disease: A Phase 2a Study Gastroenterology ·Bruce E. Sands, Jingjing Chen, Brian G. Feagan, Mark Penney, William A. Rees, Silvio Danese, Peter Higgins, Paul Newbold, Raffaella Faggioni, Kaushik Patra, Jing Li, Paul Klekotka, Chris Morehouse, Erik Pulkstenis, Jörn Drappa, René van der Merwe, Robert A. Gasser	2017	223
3	Expression of hypoxia‐inducible factor 1α in tumours of patients with glioblastoma Neuropathology and Applied Neurobiology ·K. L. Søndergaard, David A. Hilton, Mark Penney, Martin Ollerenshaw, Andrew Demaine	2002	75
4	A randomised, placebo-controlled trial of anti–interleukin-1 receptor 1 monoclonal antibody MEDI8968 in chronic obstructive pulmonary disease Respiratory Research ·Peter M.A. Calverley, Sanjay Sethi, Michelle Dawson, Christine K. Ward, Donna K. Finch, Mark Penney, Paul Newbold, René van der Merwe	2017	74
5	Structural and functional characterization of a specific antidote for ticagrelor Blood ·Andrew Buchanan, Philip M. Newton, S. KENNETH PEHRSSON, Tord Inghardt, Thomas Antonsson, Peder Svensson, Tove Sjögren, Linda Öster, Annika Janefeldt, Ann-Sofie Sandinge, Feenagh Keyes, Mark Austin, Jennifer Spooner, Peter Gennemark, Mark Penney, Garnet E. Howells, Tristan J. Vaughan, Sven Nylander	2015	64
6	Preclinical QSP Modeling in the Pharmaceutical Industry: An IQ Consortium Survey Examining the Current Landscape CPT Pharmacometrics & Systems Pharmacology ·Marjoleen Nijsen, Fan Wu, Loveleena Bansal, Erica L. Bradshaw‐Pierce, Jason R. Chan, Bianca M. Liederer, Jerome T. Mettetal, Patricia Schroeder, Edgar Schuck, Alice Tsai, Christine Xu, Anjaneya Chimalakonda, Kha Le, Mark Penney, Brian Topp, Akihiro Yamada, Mary E. Spilker	2018	64
7	Applications of Quantitative Systems Pharmacology in Model‐Informed Drug Discovery: Perspective on Impact and Opportunities CPT Pharmacometrics & Systems Pharmacology ·Erica L. Bradshaw, Mary E. Spilker, Richard Zang, Loveleena Bansal, Handan He, Rhys D.O. Jones, Kha Le, Mark Penney, Edgar Schuck, Brian Topp, Alice Tsai, Christine Xu, Marjoleen Nijsen, Jason R. Chan	2019	60
8	Specificity of lymphoreticular accumulation of prion protein for variant Creutzfeldt–Jakob disease Journal of Clinical Pathology ·David A. Hilton, Judit Sutak, Maynard Smith, Mark Penney, Lisa Conyers, P. G. Edwards, Linda McCardle, Diane Ritchie, Mark Head, Clayton A. Wiley, James W. Ironside	2004	51
9	Best Practices to Maximize the Use and Reuse of Quantitative and Systems Pharmacology Models: Recommendations From the United Kingdom Quantitative and Systems Pharmacology Network CPT Pharmacometrics & Systems Pharmacology ·L. Cucurull-Sanchez, Michael J. Chappell, Vijayalakshmi Chelliah, S. Y. Amy Cheung, Gianne Derks, Mark Penney, Alex Phipps, Rahuman S. Malik‐Sheriff, Jon Timmis, Marcus J. Tindall, Piet H. van der Graaf, Paolo Vicini, James Yates	2019	42
10	Histological indicators of prognosis in glioblastomas: retinoblastoma protein expression and oligodendroglial differentiation indicate improved survival Histopathology ·D. A. Hilton, Mark Penney, Louis Pobereskin, Hayley M. Sanders, Seth Love	2004	31
11	Evaluation of Molecular Markers in Low-Grade Diffuse Astrocytomas The American Journal of Surgical Pathology ·David A. Hilton, Mark Penney, Barry J. Evans, Hilary Sanders, Seth Love	2002	23
12	Evaluation of In Vitro Models for Assessment of Human Intestinal Metabolism in Drug Discovery Drug Metabolism and Disposition ·Mari Davies, Prabha Peramuhendige, Lloyd King, Melanie Golding, Apoorva Kotian, Mark Penney, Syeda A.B. Shah, Nenad Manevski	2020	22
13	830 Initial Evaluation of MEDI2070 (Specific Anti-IL-23 Antibody) in Patients With Active Crohn's Disease Who Have Failed Anti-TNF Antibody Therapy: A Randomized, Double-Blind Placebo-Controlled Phase 2A Induction Study Gastroenterology ·Bruce E. Sands, Jingjing Chen, Mark Penney, Paul Newbold, Raffaella Faggioni, René van der Merwe, Kaushik Patra, Paul Klekotka, Erik Pulkstenis, Jörn Drappa, Robert A. Gasser	2015	18
14	Effects of IL‐1β–Blocking Therapies in Type 2 Diabetes Mellitus: A Quantitative Systems Pharmacology Modeling Approach to Explore Underlying Mechanisms CPT Pharmacometrics & Systems Pharmacology ·Rikard Palmér, Elin Nyman, Mark Penney, A Marley, Gunnar Cedersund, Balaji Agoram	2014	17
15	Recombinant sclerostin inhibits bone formation in vitro and in a mouse model of sclerosteosis Journal of Orthopaedic Translation ·T. Dreyer, Mittal Shah, Carl Doyle, Kevin Greenslade, Mark Penney, Paul I. Creeke, Apoorva Kotian, Hua Zhu Ke, Vinny Naidoo, Gill Holdsworth	2021	14
16	At the bench: the key role of PK–PD modelling in enabling the early discovery of biologic therapies British Journal of Clinical Pharmacology ·Mark Penney, Balaji Agoram	2013	9
17	Unraveling the pharmacokinetic interaction of ticagrelor and MEDI2452 (Ticagrelor antidote) by mathematical modeling CPT Pharmacometrics & Systems Pharmacology ·J.O. Almquist, Mark Penney, S. KENNETH PEHRSSON, A‐S Sandinge, Annika Janefeldt, Suhail Maqbool, Shimona Madalli, James R. Goodman, Sven Nylander, Peter Gennemark	2016	8
18	A mechanistic PK/PD model of AZD0171 (anti‐LIF) to support Phase II dose selection CPT Pharmacometrics & Systems Pharmacology ·Azar Shahraz, Mark Penney, Juliana Candido, Grace Opoku‐Ansah, Melanie Neubauer, Jim Eyles, Oluwaseun O. Ojo, Nelson F. Liu, Nadia Luheshi, Alex Phipps, Karthick Vishwanathan	2024	2

About Mark Penney

Mark Penney is a scholar working on Molecular Biology, Oncology, Hematology, Immunology and Genetics, having authored 18 papers that have together received 1.1k indexed citations. Recurring topics across this work include Computational Drug Discovery Methods (3 papers), Glioma Diagnosis and Treatment (3 papers), Pharmacogenetics and Drug Metabolism (2 papers), Antiplatelet Therapy and Cardiovascular Diseases (2 papers), Inflammatory Bowel Disease (2 papers), Cancer, Hypoxia, and Metabolism (2 papers), Cancer-related Molecular Pathways (2 papers) and Platelet Disorders and Treatments (2 papers). The work is most often cited by research in Internal Medicine (46 citations), Neurology (100 citations), Immunology (207 citations), Genetics (82 citations) and Genetics (209 citations). Mark Penney has collaborated with scholars based in United Kingdom, United States and Sweden. Frequent co-authors include David A. Hilton, Linda McCardle, James W. Ironside, Diane Ritchie, P. G. Edwards, Doha Hegazy, Azra C. Ghani, René van der Merwe, Paul Newbold and Erik Pulkstenis. Their work appears in journals such as CPT Pharmacometrics & Systems Pharmacology, Gastroenterology, Journal of Clinical Pathology, Journal of Orthopaedic Translation and Blood.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact